helioxanthin 8-1 profile

helioxanthin 8-1: an antiviral agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	6320331
CHEMBL ID	369673
SCHEMBL ID	2948826
MeSH ID	M0555185

Synonym
1,3-benzodioxolo[4,5-g]phthalazine-7,10-dione, 11-(1,3-benzodioxol-5-yl)-8,9-dihydro-
11-(1,3-benzodioxol-5-yl)-8,9-dihydro-[1,3]benzodioxolo[7,6-g]phthalazine-7,10-dione
CHEMBL369673
CS-3198
HY-16680
helioxanthin 8-1
SCHEMBL2948826
840529-13-7
AKOS027384118
F85045
MS-26099

Bioassays (57)

Assay ID	Title	Year	Journal	Article
AID358104	Antiviral activity against HSV1	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358067	Antiviral activity against HBV in mouse ayw wild type HBV-Met cells assessed as inhibition of viral DNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358091	Decrease in binding of HBV promoter preC/C-EnhII to HNF4-1 in human HepG2 cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358092	Decrease in binding of HBV promoter preC/C-EnhII to HNF4-2 in human HepG2 cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID251782	Percent inhibition against Hepatitis C virus replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358089	Decrease in binding of HBV promoter preC/C-EnhII to human HNF3 in HepG2(2.2.15) cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358077	Cytotoxicity against HBV transfected human adriamycin-resistant wild type HepW10 cells by MTT assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358065	Antiviral activity against HBV in adriamycin-resistant wild type HepW10 cells assessed as inhibition of viral DNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358101	Decrease in HBV protein level in human HepG2 cells at 2 uM after 18 to 24 hrs by time course study	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358094	Decrease in binding of HBV promoter preC/C-EnhII to FTF2 in human HepG2 cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358075	Antiviral activity against HBV in mouse HBV-Met cells assessed as inhibition of viral 2.4/2.1RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358083	Effect on HBV viral core protein degradation on cyclohexamide terminated cellular protein synthesis in human HepG2(2.2.15) cells at 0.3 uM	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358073	Antiviral activity against HBV in human HepW10 cells assessed as inhibition of viral 2.4/2.1RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID249056	Cytotoxicity against CEM cell lines of human	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358097	Down regulation of HNH3-beta in human HepG2(2.2.15) cells expressing HBV at 0.3 uM by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358102	Antiviral activity against hepatitis C virus	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358086	Inhibition of CMV promoter in human HepG2(2.2.15) cells by luciferase reporter gene assay after 16 to 24 hrs	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID1444844	Cytotoxicity against human HepG2(2.2.15) cells assessed as reduction in cell viability after 3 days by methylene blue assay	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID358107	Antiviral activity against HBV assessed as inhibition of viral replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID249057	Cytotoxicity against MT-2 cell lines of human	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358099	Down regulation of HNH3-alpha mRNA in human HepG2(2.2.15) cells expressing HBV at 0.3 uM by Northern blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358084	Inhibition of HBV promoter in human HepG2(2.2.15) cells by luciferase reporter gene assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246412	Effective concentration to inhibit 50% of herpes simplex virus type 1 replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358070	Antiviral activity against HBV in human HepD2 cells assessed as inhibition of viral pre genomic RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358087	Decrease in binding of HBV promoter preC/C-EnhII to human HNF4-1 in HepG2(2.2.15) cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246491	Effective concentration to inhibit 50% of cytomegalovirus (CMV) replication in a cell culture model;ND=Not determined	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358071	Antiviral activity against HBV in HBV-Met cells assessed as inhibition of viral pre genomic RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358080	Cytotoxicity against HBV transfected human HepG2 cells by MTT assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358105	Antiviral activity against Epstein-Barr virus	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358095	Down regulation of HNH4-alpha in human HepG2(2.2.15) cells expressing HBV at 0.3 uM by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358074	Antiviral activity against HBV in human HepD2 cells assessed as inhibition of viral 2.4/2.1RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358098	Down regulation of HNH3-beta in human HepG2 cells expressing HBV at 0.3 uM by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246328	Effective concentration to inhibit 50% of hepatitis B virus replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358088	Decrease in binding of HBV promoter preC/C-EnhII to human HNF4-2 in HepG2(2.2.15) cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246329	Effective concentration to inhibit 50% of hepatitis C virus replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358069	Antiviral activity against HBV in human HepW10 cells assessed as inhibition of viral pre genomic RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246342	Effective concentration to inhibit 50% of epstein Barr virus replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID1444845	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA level after 6 days by Southern blot analysis	2017	Journal of medicinal chemistry, 08-10, Volume: 60, Issue:15	Past, Current, and Future Developments of Therapeutic Agents for Treatment of Chronic Hepatitis B Virus Infection.
AID358096	Down regulation of HNH4-alpha in human HepG2 cells expressing HBV at 0.3 uM by Western blotting	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358066	Antiviral activity against HBV in adriamycin-resistant HepD2 cells with RTM20V and RTV180M mutation assessed as inhibition of viral DNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID1072531	Antiviral activity against Hepatitis B virus	2014	European journal of medicinal chemistry, Mar-21, Volume: 75	A review of non-nucleoside anti-hepatitis B virus agents.
AID358100	Decrease in HBV RNA in human HepG2 cells at 2 uM after 18 to 24 hrs by time course study	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358079	Cytotoxicity against HBV transfected mouse ayw wild type HBV-Met cells by MTT assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358064	Antiviral activity against HBV in ayw wild type HepG2(2.2.15) cells assessed as inhibition of viral DNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358103	Antiviral activity against HIV	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358106	Antiviral activity against human papilloma virus 11	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358108	Decrease in HBV DNA level in human HepG2 cells at 2 uM after 48 hrs by time course study	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358085	Inhibition of HBV promoter in human HepG2 cells by luciferase reporter gene assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358068	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral pre-genomic RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246413	Effective concentration to inhibit 50% of herpes simplex virus type 2 replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358093	Decrease in binding of HBV promoter preC/C-EnhII to HNF3 in human HepG2 cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358081	Effect on virus RNA stability on doxycyclin-induced HBV pre genomic RNA production in Met-On-TRE HBV cells treated with 0.3 uM drug after doxycycline removal	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358078	Cytotoxicity against HBV transfected human adriamycin-resistant HepD2 cells with RTM20V and RTV180M mutation by MTT assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID246416	Effective concentration to inhibit 50% of human immunodeficiency virus replication in a cell culture model	2005	Journal of medicinal chemistry, Jan-27, Volume: 48, Issue:2	Synthesis and antiviral activity of helioxanthin analogues.
AID358076	Cytotoxicity against HBV transfected human ayw wild type HepG2(2.2.15) cells by MTT assay	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358090	Decrease in binding of HBV promoter preC/C-EnhII to human FTF in HepG2(2.2.15) cells	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
AID358072	Antiviral activity against HBV in human HepG2(2.2.15) cells assessed as inhibition of viral 2.4/2.1RNA replication	2007	Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20	Unique antiviral mechanism discovered in anti-hepatitis B virus research with a natural product analogue.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (40.00)	29.6817
2010's	3 (60.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	2 (40.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	3 (60.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.25	1	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
protocatechualdehyde protocatechualdehyde: found in wheat grains, wheat seedlings, & other plants; RN given refers to parent cpd; see also rancinamycins; structure	3.19	1	dihydroxybenzaldehyde
aloe emodin aloe emodin: structure distinct from emodin; this does not mean emodin from aloe. Aloe emodin : A dihydroxyanthraquinone that is chrysazin carrying a hydroxymethyl group at position 3. It has been isolated from plant species of the genus Aloe.	3.19	1	aromatic primary alcohol; dihydroxyanthraquinone	antineoplastic agent; plant metabolite
chrysophanic acid chrysophanic acid: RN given refers to parent cpd; structure in Merck, 9th ed, #2260. chrysophanol : A trihydroxyanthraquinone that is chrysazin with a methyl substituent at C-3. It has been isolated from Aloe vera and exhibits antiviral and anti-inflammatory activity.	3.19	1	dihydroxyanthraquinone	anti-inflammatory agent; antiviral agent; plant metabolite
physcione physcione: structure. physcion : A dihydroxyanthraquinone that is 9,10-anthraquinone bearing hydroxy substituents at positions 1 and 8, a methoxy group at position 3, and a methyl group at position 6. It has been widely isolated and characterised from both terrestrial and marine sources.	3.19	1	dihydroxyanthraquinone	anti-inflammatory agent; antibacterial agent; antifungal agent; antineoplastic agent; apoptosis inducer; hepatoprotective agent; metabolite
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.02	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	4.13	2	benzamides; carboxylic ester
lamivudine [no description available]	4.06	4	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
epigallocatechin gallate epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis). (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin.	3.25	1	flavans; gallate ester; polyphenol	antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite
helioxanthin helioxanthin: structure in first source. helioxanthin : A furonaphthodioxole that is furo[3',4':6,7]naphtho[1,2-d][1,3]dioxol-7(9H)-one substituted by a 1,3-benzodioxol-5-yl group at posiiton 10. It is a inhibitor of HBV, HCV and HSV-1 viruses.	4.59	4	benzodioxoles; furonaphthodioxole; lignan	anti-HBV agent; antineoplastic agent; plant metabolite
tizoxanide tizoxanide: major metabolite of nitazoxanide; structure in first source	3.25	1	salicylamides
chrysophanol 8-o-glucoside chrysophanol 8-O-glucoside: has anti-hepatitis B virus activity; also has antiplatelet and anticoagulant activities; isolated from Rheum palmatum. chrysophanol 8-O-beta-D-glucoside : A beta-D-glucoside in which the aglycone species is chrysophanol, the glycosidic linkage being to the hydroxy group at C-8.	3.19	1	beta-D-glucoside; monohydroxyanthraquinone
lignans Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)	2.05	1
dihydrochelerythrine dihydrochelerythrine: trypanocidal and antileishmanial dihydrochelerythrine derivative from Garcinia lucida; structure in first source	3.19	1	benzophenanthridine alkaloid
bay 41-4109 BAY 41-4109: structure in first source	4.13	2
hbf 0259 [no description available]	3.19	1
robustaflavone robustaflavone: bis-apigenin coupled at 6 and 3' positions; a potential non-nucleoside anti-hepatitis B agent;. robustaflavone : A biflavonoid that is obtained by oxidative coupling of two molecules of apigenin resulting in a bond between positions C-3 of the hydroxyphenyl ring and C-6 of the chromene ring. Isolated from Thuja orientalis and Rhus succedanea it exhibits antioxidant, cytotoxic and anti-hepatitis B activity.	3.25	1	biflavonoid; hydroxyflavone; ring assembly	anti-HBV agent; antineoplastic agent; antioxidant; metabolite
wogonin wogonin: structure in first source. wogonin : A dihydroxy- and monomethoxy-flavone in which the hydroxy groups are positioned at C-5 and C-7 and the methoxy group is at C-8.	3.19	1	dihydroxyflavone; monomethoxyflavone	angiogenesis inhibitor; antineoplastic agent; cyclooxygenase 2 inhibitor; plant metabolite
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	3.25	1	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	3.19	1	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
leucamide a leucamide A: a cytotoxic heptapeptide from the Australian sponge Leucetta microraphis; structure in first source	3.19	1
astragaloside IV [no description available]	3.19	1	pentacyclic triterpenoid; triterpenoid saponin	anti-inflammatory agent; antioxidant; EC 4.2.1.1 (carbonic anhydrase) inhibitor; neuroprotective agent; plant metabolite; pro-angiogenic agent
rosamultin rosamultin: isolated from roots of Rosa multiflora; RN not in Chemline 3/87; RN from Chem Abstracts Index Guide 1985	3.19	1
caudatin caudatin: antineoplastic from Cynanchum; structure in first source	3.25	1
2-hydroxybenzoyl-n-(5-chlorothiazol-2-yl)amide 2-hydroxybenzoyl-N-(5-chlorothiazol-2-yl)amide: an antiviral agent effective against hepatitis B virus; structure in first source	3.19	1
alisol f [no description available]	3.19	1
alisol a 24-acetate alisol A 24-acetate: isolated from Alismatis Rhizoma; structure in first source	3.19	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	2.02	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug

Condition	Relationship Strength	Studies
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.02	1
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	2.02	1
Hepatitis B Virus Infection [description not available]	3.01	1
Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	3.01	1
Chronic Hepatitis B [description not available]	3.06	1
Hepatitis B, Chronic INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.	3.06	1
Infections, Hepadnaviridae [description not available]	2.05	1
Hepadnaviridae Infections Virus diseases caused by the HEPADNAVIRIDAE.	2.05	1

helioxanthin 8-1

Description

Cross-References

Synonyms (11)

Bioassays (57)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.63

Study Types

helioxanthin 8-1

Description

Cross-References

Synonyms (11)

Bioassays (57)

Research

Studies (5)

Market Indicators

Research Demand Index: 12.63

Study Types

Related Drugs (28)

Related Conditions (8)